FierceBiotech

BioSante Pharmaceuticals, Inc. to Present Cancer Vaccine Portfolio Update at the BIO International Convention

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present a BioSante cancer vaccine portfolio update at the BIO International Convention, which will take place ...
FiercePharma

BioSante Pharmaceuticals Says FDA Advisory Committee Recommendation Against Flibanserin has No Impact on LibiGel®

LibiGel Clinical Studies for Safety and Efficacy Continue as per FDA-Agreed Protocols LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) commented today that the ...
AZoNano

BioSante Announces CAP Nanotechnology Product Development - New Product

BioSante Pharmaceuticals, Inc. today announced an update on recent developments of its calcium phosphate-based nanotechnology (CAP). "To date we have made significant progress in development of our ...
FiercePharma

BioSante Pharmaceuticals Announces Teva New Drug Application for Bio-T-Gel™

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug ...
FierceBiotech

BioSante Pharmaceuticals to Raise $25.1 Million in Registered Direct Offering

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has received commitments from several institutional investors to purchase $25.1 million of ...
AZoNano

BioSante Listed on Merrill Lynch, Punk Ziegel Nanotechnology Stock Indices - News Item

BioSante Pharmaceuticals, Inc. announced today that the investment firms Merrill Lynch and Punk, Ziegel & Company have included BioSante in their respective indices of nanotechnology companies. "This ...
Business Wire

BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger

BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) ...
Yahoo Finance

BioSante will merge with ANI Pharma in stock deal

NEW YORK (AP) -- BioSante Pharmaceuticals Inc. said Thursday it will merge with ANI Pharmaceuticals in an all-stock deal worth about $94 million. BioSante has spent years developing LibiGel, a ...
Business Insider

Biosante Pharmaceuticals earnings preview: what to expect

Biosante Pharmaceuticals is reporting earnings from Q4 on February 27. Wall Street analysts expect Biosante Pharmaceuticals will release earnings per share of $1.24. Follow Biosante Pharmaceuticals ...
Business Insider

Biosante Pharmaceuticals earnings preview: what Wall Street is expecting

Biosante Pharmaceuticals will report earnings from Q4 on February 27. Wall Street predict expect Biosante Pharmaceuticals will release earnings per share of $1.16. Go here to track Biosante ...
MarketWatch

BioSante: Libigel falls short in study

BioSante Pharmaceuticals Inc. BPAX said a testosterone gel it has been developing to treat female sexual dysfunction fell short of its main endpoints, sending shares plummeting after hours. Shares ...